Pembrolizumab in Triple-Negative Breast Cancer. Reply
N Engl J Med
.
2022 Oct 13;387(15):1436.
doi: 10.1056/NEJMc2210919.
Authors
Javier Cortes
1
,
Xuan Zhou
2
,
Peter Schmid
3
Affiliations
1
International Breast Cancer Center, Barcelona, Spain jacortes@vhio.net.
2
Merck, Rahway, NJ.
3
Queen Mary University of London, London, United Kingdom.
PMID:
36239658
DOI:
10.1056/NEJMc2210919
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Triple Negative Breast Neoplasms* / drug therapy
Substances
Antibodies, Monoclonal, Humanized
pembrolizumab